0.75
+0.0158(+2.16%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.74 |
| Day High | 0.78 |
| Day Low | 0.68 |
| 52-Week High | 3.85 |
| 52-Week Low | 0.54 |
| Volume | 2.06M |
| Average Volume | 1.55M |
| Market Cap | 7.93M |
| PE | -0.21 |
| EPS | -3.5 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 1.53 |
| Change | 0.02 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $0.88 as of January 20, 2026 at a share price of $0.746. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $3.32 as of January 20, 2026 at a share price of $0.746.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GlobeNewswire Inc.
Jan 15, 2026 1:30 PM GMT
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 SAN FRANCISCO, CALIFORNIA, J
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 14, 2025 2:00 PM GMT
Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumor
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GlobeNewswire Inc.
Oct 08, 2025 1:00 PM GMT
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promis